据强化疗法报告,在安全性提高的情况下,在标准治疗前用INT230-6治疗的早期三阴性乳腺癌患者中,肿瘤反应率为71.4%。 Intensity Therapeutics reports a 71.4% tumor response in early triple-negative breast cancer patients treated with INT230-6 before standard therapy, with improved safety.

强度治疗学报告说,其第二阶段INVINCICUBLE-4试验早期三联阴性乳腺癌试验取得了有希望的早期结果,表明在接受标准治疗前获得INT230-6的病人中,病理学完全反应率为71.4%,而仅接受标准治疗的病人就占33%。 Intensity Therapeutics reported promising early results from its Phase 2 INVINCIBLE-4 trial for early-stage triple-negative breast cancer, showing a 71.4% pathological complete response rate in patients who received INT230-6 before standard therapy, compared to 33% in those receiving standard treatment alone. 该公司提交了一项协议修正案,以便在2025年9月因皮肤刺激而暂停注册后恢复注册,目前使用较低的毒品量和单次注射。 The company has submitted a protocol amendment to resume enrollment after pausing in September 2025 due to skin irritations, now using a lower drug volume and single injection. 安全数据仍然有利,INT230-6组的严重不利事件较少。 Safety data remain favorable, with fewer severe adverse events in the INT230-6 group. 迄今为止,在61名计划治疗的病人中,已有14人得到治疗。 So far, 14 of 61 planned patients have been treated.